Sinovac Biotech Ltd. $(SVA)$ has announced a delay in filing its annual report on Form 20-F for the financial year ending December 31, 2024. The company received a notification from Nasdaq on May 16, 2025, regarding non-compliance with Nasdaq Listing Rule 5250(c)(1) due to this delay. Sinovac is working on selecting a new independent registered public accounting firm after the resignation of Grant Thornton Zhitong. The company aims to submit a compliance plan by July 15, 2025, to address the issue.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.